“It becomes scarier the more you learn about it and the more new studies are coming up. Instead of making it better, every new study demonstrates some new alarming outcome.” During the COVID-19 pandemic, Dr. Mobeen Syed, also known as DrBeen, noticed there was a lack of unbiased, accessible information about both the virus and…
Dr. Mobeen Syed: Pandemic Destruction and the Emergence of Anti-Antibodies
[PREMIERING 7/6, 7:30PM ET] Dr. Mobeen Syed: Pandemic Destruction and the Emergence of Anti-Antibodies
“It becomes scarier the more you learn about it and the more new studies are coming up. Instead of making it better, every new study demonstrates some new alarming outcome.” During the COVID-19 pandemic, Dr. Mobeen Syed, also known as DrBeen, noticed there was a lack of unbiased, accessible information about both the virus and…
Study Reveals Remarkable Reversal of Previously Incurable Heart Failure Condition
In a groundbreaking development, a recent study revealed that three men have successfully reversed their previously incurable heart failure condition. The condition, transthyretin cardiac amyloidosis, is characterized by the accumulation of sticky and toxic proteins in and around the heart. Typically, patients diagnosed with this condition face a grim prognosis, with approximately half succumbing to…
Eggs May Hold the Key to a New COVID-19 Treatment
Multiple studies published in the last two years indicate that eggs from chickens immunized against SARS-CoV-2 could be used to create effective treatments against COVID-19 in humans. There is no evidence, however, that this development is responsible for the current egg shortage in the United States, as some conspiracy theories allege. In a study published…
Eli Lilly to Make COVID-19 Antibody Drug Commercially Available From August
Eli Lilly and Co. said on Wednesday it plans to make its COVID-19 antibody drug commercially available to U.S. states as well as hospitals and other healthcare providers from August. The drug, bebtelovimab, had received authorization in the United States in February for the treatment of mild-to-moderate COVID-19 among adults and children. Eli Lilly entered…
AstraZeneca’s Imfinzi Fails Main Goal in Advanced Cervical Cancer Study
AstraZeneca said on Thursday its drug Imfinzi, along with chemoradiotherapy, failed to achieve the main goal of improving survival in patients with locally advanced cervical cancer without the disease worsening. The late-stage study, dubbed “CALLA,” tested progression-free survival of patients with the combination against chemoradiotherapy alone, the drugmaker said, and the results are seen as…
9 in 10 Young Teens in UK Likely to Have CCP Virus Antibodies: ONS Analysis
At the beginning of January, around 9 in 10 young teenagers in the UK had either previously had COVID-19 or been vaccinated against the CCP virus, official analysis suggests. The Office for National Statistics (ONS) estimated that the percentages of children aged between 12 and 15 who were likely to test positive for CCP (Chinese…
What Is Original Antigenic Sin and Why Do We Care?
Commentary As the United States feverishly rolls out COVID-19 vaccination “booster” shots, Israel is reporting trudging toward a fourth shot in response to evidence of waning immunity protection and rapidly increasing cases after its widespread administration of a third shot last fall. Notably, all of these shots continue to use the original, long-extinct wild-type variant…
Global License Deal Will ‘Turn the Tide’ on Pandemic, WHO Says
The World Health Organization (WHO) on Tuesday said it has finalized a global license deal to ramp up production of a serological technology that detects COVID-19 antibodies, something the agency says will “turn the tide” on the pandemic. The license will be provided royalty-free to poor and middle-income countries, the WHO announced in a news…
AstraZeneca Says Drug Cocktail Effective Against COVID-19 in Late-Stage Study
European drugmaker AstraZeneca this week said a late-stage study showed its antibody drug cocktail is effective at keeping COVID-19 patients out of hospitals. The phase 3 trial preliminary results showed the drug, a long acting antibody (LAAB) combination, cut the risk of developing severe COVID-19 or dying by 50 percent compared to a placebo in people…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`